PharmD Live LLC

MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. FLORetina aims to provide cutting-edge insights on research and clinical development from world-leading experts in the field of medical retina, retinal surgery, and imaging. Details are as follows: Session:Retina Futura 1: Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical UpdatesDate:Friday, December 6, 2024, 11:25 AM CETPresentation:Beyond VEGF-A Inhibition: Will Blocking VEGF-C and VEGF-D Lead to Better Outcomes?Presenter:Professor Adnan Tufail, MBBS, MD, FRCOphthProgram:https://floretina.com/floretinaicoormeeting2024/program About Opthea Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone. To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn. Authorized for release to ASX by Frederic Guerard, PharmD, CEO Investor InquiriesPJ Kelleher LifeSci Advisors, LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430-7579 Media InquiriesSilvana Guerci-LenaNorthStream Global PartnersEmail: silvana@nsgpllc.com Join our email database to receive program updates:Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com Source: Opthea Limited

MELBOURNE, Australia and PRINCETON, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Fred Guerard, PharmD, Chief Executive Officer, will host one-on-one meetings with investors and participate in a panel presentation during the Citi 2024 Global Healthcare Conference on December 5, 2024 in Miami, Florida. Details are as follows: Panel:Eyes Wide Open on OphthalmologyPresenter:Frederic Guerard, PharmD, CEO, OptheaDate:Thursday, December 5, 2024, 1:45 PM ET The webcast will be accessible on the “Events & Presentations” section of the Company’s website at http://ir.opthea.com/. About Opthea Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone. To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn. Authorized for release to ASX by Frederic Guerard, PharmD, CEO Investor InquiriesPJ Kelleher LifeSci Advisors, LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430-7579 Media Inquiries Silvana Guerci-Lena NorthStream Global Partners Email: silvana@nsgpllc.com Join our email database to receive program updates:Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.comSource: Opthea Limited

WASHINGTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- In recognition of American Diabetes Month this November, PharmD Live, an innovative pharmacist-led virtual care solution powered by AI-driven algorithms, underscores the critical role of its Pharmacist Care Managers (PCMs) to optimize diabetes management and close care gaps created by national retail pharmacy chains shuttering primary care clinics and eliminating virtual care options. PharmD Live’s innovative pharmacist-led telehealth care model enables continuous patient engagement, providing millions of people, especially those in underserved communities, consistent access to vital services. “Managing diabetes requires multiple medications, lifestyle changes and regular monitoring, which can overwhelm the estimated 38 million Americans living with the disease,” says Cynthia Chioma Nwaubani, PharmD, BCGP, CEO and founder, PharmD Live. “PharmD Live’s PCMs provide continuous monitoring and education to support medication adherence, which is crucial for diabetes management where blood sugar levels, medications and lifestyle are interdependent. Now more than ever, this is vital given the cessation of services typically provided by retail pharmacists. PCMs are specially trained to help patients adhere to treatment regimens, understand complex health information and feel supported every step of the way.” Integrating PharmD Live into a clinic setting, healthcare system or provider organization (accountable care organization or integrated delivery network) lessens the impact of provider shortage and retail pharmacy virtual care closures, prevents disruptions in patient care and supports better health outcomes for diverse communities. Healthcare entities participating in value-based care models improve care quality metrics, enhance outcomes and boost shared savings contracts without any up-front costs. “PCMs manage patients’ medication needs remotely, maintaining the quality of care that virtual care services via chain pharmacy closures could otherwise disrupt,” continues Dr. Nwaubani. “Patients and providers can expect expert support for remote patient monitoring, medication therapy management, chronic disease support and education and virtual medication refills and delivery coordination.” About PharmD Live PharmD Live is a leading innovator in virtual clinical pharmacist solutions, dedicated to revolutionizing chronic care and medication management. Founded with a vision to improve patient outcomes and streamline healthcare delivery, PharmD Live combines the expertise of clinical pharmacist care managers supported by cutting-edge AI technology to provide scalable, quality care solutions. Our platform empowers physicians with actionable clinical intelligence, enabling them to deliver high-quality, personalized care while enhancing revenue through participation in value-based care programs. https://www.pharmdlive.com/